Rosen Law says Embecta investors may seek lead-plaintiff role in securities suit
Rosen Law Firm said Embecta Corp. investors who bought common stock between Nov. 25, 2025, and May 4, 2026, may ask to join a securities class action before an Aug. 17, 2026, deadline.
Rosen Law Firm said Embecta Corp. investors who bought common stock between Nov. 25, 2025, and May 4, 2026, may ask to join a securities class action. The lead-plaintiff deadline is Aug. 17, 2026.
Rosen said a class action has already been filed. The notice says investors who believe they were affected by the company’s disclosures can ask the court to serve as lead plaintiff.
According to the Aug. 17, 2026, PR Newswire notice, Embecta trades on Nasdaq under the ticker EMBC. The firm said investors in the class period may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket fees or costs.
The notice said the lead plaintiff acts as a representative for other class members and directs the litigation. It also provided a case-join link and contact information for Phillip Kim, Esq.
Rosen’s summary of the allegations said defendants made false or misleading statements or concealed material adverse facts about Embecta’s fiscal results. The notice also said Embecta allegedly knew or recklessly disregarded that its guidance was misleading and unattainable.
In the same notice, Rosen said Embecta described its pen needle business as “incredibly resolute” before the company missed expectations and cut fiscal 2026 guidance. The notice said investors allegedly suffered damages when the true details entered the market.
Rosen Law Firm also included marketing statements about its securities class action experience, recoveries and rankings in the release.
Investors who want to seek lead-plaintiff status must move the court by Aug. 17, 2026, according to the release.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.